IXODES

Ixodes is a pre-clinical stage biotechnology company specializing in the prevention of tick-borne illnesses, with a primary focus on Lyme disease. Established as a joint spin-off from the University of Antwerp and the University of Lille, the company develops vaccines that target tick salivary proteins to prevent the transmission of pathogens from the tick to the human host. Unlike traditional vaccines that target specific bacteria, Ixodes' approach aims to provide broad protection by interfering with the tick's feeding mechanism. The company is backed by prominent European life science investors and leverages deep expertise in tick biology and immunology to address a significant unmet need in infectious disease prevention.